Modern Synthesis, a London, UK-based biotechnology company advancing microbially-derived biomaterials, raised $5.5M in funding.
The round was by Extantia Capital with participation from Artesian, Collab Fund, and others.
The company intends to use the funds to expand operations and its development efforts.
Co-founded by Jen Keane, CEO and Ben Reeve, CTO, Modern Synthesis is a biotechnology company developing microbially-derived biomaterials. It transforms nanocellulose , a natural fermentation-derived fibre , into durable alternatives to animal leather, ‘vegan’ leather, and plastic-based coated textiles. The resulting materials are free from petrochemicals and toxic ingredients, and offer reduced environmental impact compared to incumbent textiles.
FinSMEs
11/02/2025